Takeda (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency or secondary immunodeficiency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Keros Therapeutics price target lowered to $43 from $100 at Truist
- Takeda Announces Subsidiary Liquidation and Merger Completion
- Hutchmed to receive milestone payment from Takeda
- Takeda, Keros Therapeutics enter exclusive elritercept license agreement
- Keros Therapeutics announces global license agreement with Takeda